| Symbol | JSPR |
|---|---|
| Name | JASPER THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Address | 2200 BRIDGE PKWY SUITE #102, REDWOOD CITY, California, 94065, United States |
| Telephone | +1 650 - 549-1400 |
| Fax | — |
| — | |
| Website | https://www.jaspertherapeutics.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001788028 |
| Description | Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy. Additional info from NASDAQ: |
2026-08-14 20:07
(30% Negative) JASPER THERAPEUTICS, INC. (JSPR) Reports Q3 2026 Financial Results
Read more
2026-08-14 15:00
Jasper Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Read more
2026-08-14 15:00
Jasper Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Read more
2026-08-03 20:47
(99% Neutral) JASPER THERAPEUTICS, INC. (JSPRW) Announces Regulatory Update
Read more
2026-07-31 10:06
(99% Neutral) JASPER THERAPEUTICS, INC. (JSPR) Announces Business Combination
Read more
2026-07-23 17:01
New Form 3 - Jasper Therapeutics, Inc. <b>Filed:</b> 2026-07-23 <b>AccNo:</b> 0001213900-26-080864 <b>Size:</b> 20 KB
Read more
2026-07-22 23:10
Ros Matthew E 🟢 acquired 53.7K shares (1 derivative) of Jasper Therapeutics, Inc. (JSPR) Transaction Date: Jul 20, 2026 | Filing ID: 080525
Read more
2026-07-22 20:11
New Form 3 - Jasper Therapeutics, Inc. <b>Filed:</b> 2026-07-22 <b>AccNo:</b> 0001213900-26-080524 <b>Size:</b> 28 KB
Read more
2026-07-22 20:11
New Form 3 - Jasper Therapeutics, Inc. <b>Filed:</b> 2026-07-22 <b>AccNo:</b> 0001213900-26-080523 <b>Size:</b> 21 KB
Read more
2026-07-21 00:38
Director Crutcher Patrick J 🟢 acquired 15.9K shares (2 derivative) of Jasper Therapeutics, Inc. (JSPR) at $0.77 Transaction Date: Jul 16, 2026 | Filing ID: 079764
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT06592768 | A Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Safety… | Phase1 | Allergic Asthma | Terminated | 2024-11-26 | 2025-08-11 | ClinicalTrials.gov |
| NCT06736262 | A Phase 2, Open-Label, Extension Study to Evaluate Long Term Safety and Clinica… | Phase2 | Urticaria Chronic | Terminated | 2024-11-26 | 2026-07-21 | ClinicalTrials.gov |
| NCT06353971 | A Dose Escalation Trial of Safety, Pharmacokinetic/Pharmacodynamic and Prelimin… | Phase1 | Chronic Inducible Urticaria | Terminated | 2024-03-18 | 2025-07-31 | ClinicalTrials.gov |
| NCT06053567 | Community-based Smoking Cessation Treatment for Adults With High Stress Sensiti… | Phase3 | Nicotine Dependence | Recruiting | 2023-12-27 | 2029-06-30 | ClinicalTrials.gov |
| NCT06162728 | Dose Escalation Trial Of Safety, Pharmacokinetic/Pharmacodynamic And Preliminar… | Phase1 | Chronic Spontaneous Urticaria | Completed | 2023-11-29 | 2026-07-08 | ClinicalTrials.gov |
| NCT05903274 | JSP191 (briquilimab) in Subjects with LR-MDS | Phase1 | Lower-risk Myelodysplastic Syndrome | Terminated | 2023-06-19 | 2024-10-21 | ClinicalTrials.gov |
| NCT06146738 | The PALSUR-study: Palliative Care Versus Surgery in High-grade Glioma Patients … | — | Glioblastoma | Recruiting | 2023-01-01 | 2029-01-01 | ClinicalTrials.gov |
| NCT06146725 | The RESBIOP-study: Resection Versus Biopsy in High-grade Glioma Patients (ENCRA… | — | Glioblastoma | Recruiting | 2023-01-01 | 2029-01-01 | ClinicalTrials.gov |
| NCT05467683 | CO2 Reactivity as a Biomarker of Non-Response to Exposure-Based Therapy | Na | Obsessive-Compulsive Disorder | Recruiting | 2022-11-02 | 2027-02-28 | ClinicalTrials.gov |
| NCT06118723 | The SUPRAMAX Study: Supramaximal Resection Versus Maximal Resection for High-Gr… | — | Glioblastoma | Recruiting | 2022-01-01 | 2028-01-01 | ClinicalTrials.gov |
| NCT04429191 | JSP191 Antibody Conditioning Regimen in MDS/AML Subjects Undergoing Allogenic H… | Phase1 | MYELODYSPLASTIC SYNDROME; MDS | Unknown | 2020-07-08 | 2023-12-08 | ClinicalTrials.gov |
| NCT03083353 | Isradipine Enhancement of Virtual Reality Cue Exposure for Smoking Cessation | Early_Phase1 | Nicotine Dependence | Completed | 2020-01-22 | 2023-06-14 | ClinicalTrials.gov |
| NCT03554785 | Comparative Effectiveness Research to Improve the Health of Sexual and Gender M… | Na | LGBT Health | Completed | 2018-03-01 | 2023-05-31 | ClinicalTrials.gov |
| NCT03325777 | Approach Bias Retraining to Augment Smoking Cessation | Na | Nicotine Dependence | Completed | 2017-11-29 | 2021-10-08 | ClinicalTrials.gov |
| NCT03152214 | Physical Activity and Community Engagement (PACE) Among Returning Veterans | Na | Reintegration | Completed | 2017-09-01 | 2019-05-01 | ClinicalTrials.gov |
| NCT03080090 | YMCA Exercise Intervention for Smoking Cessation Study | Na | Nicotine Dependence | Completed | 2017-04-12 | 2020-07-06 | ClinicalTrials.gov |
| NCT03083340 | Implementation of a Self-Help Depression Program Among Orthopedic Patients | Na | MDD | Withdrawn | 2017-04-01 | 2017-08-01 | ClinicalTrials.gov |
| NCT02963064 | JSP191 Antibody Targeting Conditioning in SCID Patients | Phase1 | SCID | Terminated | 2017-03-20 | 2025-07-07 | ClinicalTrials.gov |
| NCT02481752 | The Effect of AAT Training in Smokers | Na | Tobacco Use | Completed | 2015-07-01 | 2016-03-01 | ClinicalTrials.gov |
| NCT02482805 | Hormones and Social Anxiety Disorder Treatment | Na | Social Anxiety Disorder | Completed | 2015-07-01 | 2017-04-01 | ClinicalTrials.gov |
| NCT02181179 | Examining Yoga's Effects on Smoking | Na | Yoga | Completed | 2014-07-01 | 2017-07-01 | ClinicalTrials.gov |
| NCT02066792 | Dose Timing of D-Cycloserine to Augment CBT for Social Anxiety Disorder | Early_Phase1 | Social Anxiety Disorder | Completed | 2014-04-01 | 2018-07-01 | ClinicalTrials.gov |
| NCT00251030 | A Study To Estimate The Effect Of Omeprazole On The Pharmacokinetics Of Nelfina… | Phase4 | Healthy Volunteers | Completed | 2005-11-01 | 2006-01-01 | ClinicalTrials.gov |
Total clinical trials: 23
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Placebo | Other | Phase PHASE1 | Chronic Spontaneous Urticaria | COMPLETED | NCT06162728 |
| Briquilimab | Other | Phase PHASE1 | Chronic Spontaneous Urticaria | COMPLETED | NCT06162728 |
| Briquilimab | Other | Phase PHASE2 | Urticaria Chronic | TERMINATED | NCT06736262 |
| Cognitive Behavioral Therapy | Drug | Phase EARLY_PHASE1 | Social Anxiety Disorder | COMPLETED | NCT02066792 |
| Placebo | Other | Phase EARLY_PHASE1 | Social Anxiety Disorder | COMPLETED | NCT02066792 |
| D-Cycloserine | Other | Phase EARLY_PHASE1 | Social Anxiety Disorder | COMPLETED | NCT02066792 |
| SHAM Training | Other | Approved | Tobacco Use | COMPLETED | NCT02481752 |
| Approach Avoidance Training | Other | Approved | Tobacco Use | COMPLETED | NCT02481752 |
| SHAM Training | Other | Approved | Nicotine Dependence | COMPLETED | NCT03325777 |
| Approach Bias Retraining | Other | Approved | Nicotine Dependence | COMPLETED | NCT03325777 |
| Community Engagement | Other | Approved | Reintegration | COMPLETED | NCT03152214 |
| Vigorous Intensity Aerobic Exercise and Community Engagement | Other | Approved | Reintegration | COMPLETED | NCT03152214 |
| Smoking Cessation Intervention | Other | Approved | Nicotine Dependence | COMPLETED | NCT03080090 |
| Aerobic exercise | Other | Approved | Nicotine Dependence | COMPLETED | NCT03080090 |
| Cue Exposure | Other | Phase EARLY_PHASE1 | Nicotine Dependence | COMPLETED | NCT03083353 |
| Isradipine | Other | Phase EARLY_PHASE1 | Nicotine Dependence | COMPLETED | NCT03083353 |
| Yoga | Other | Approved | Yoga | COMPLETED | NCT02181179 |
| Cognitive Behavioral Therapy | Drug | Approved | Social Anxiety Disorder | COMPLETED | NCT02482805 |
| Deprexis | Other | Approved | MDD | WITHDRAWN | NCT03083340 |
| Exposure-Based Therapy | Drug | Approved | Obsessive-Compulsive Disorder | RECRUITING | NCT05467683 |
| Nicotine patch | Other | Phase PHASE3 | Nicotine Dependence | RECRUITING | NCT06053567 |
| Counseling | Other | Phase PHASE3 | Nicotine Dependence | RECRUITING | NCT06053567 |
| Aerobic Exercise | Other | Phase PHASE3 | Nicotine Dependence | RECRUITING | NCT06053567 |
| Nicotine patch | Other | Phase PHASE3 | Nicotine Dependence | RECRUITING | NCT06053567 |
| Counseling | Other | Phase PHASE3 | Nicotine Dependence | RECRUITING | NCT06053567 |
| Aerobic Exercise | Other | Phase PHASE3 | Nicotine Dependence | RECRUITING | NCT06053567 |
| Nicotine patch | Other | Phase PHASE3 | Nicotine Dependence | RECRUITING | NCT06053567 |
| Counseling | Other | Phase PHASE3 | Nicotine Dependence | RECRUITING | NCT06053567 |
| Aerobic Exercise | Other | Phase PHASE3 | Nicotine Dependence | RECRUITING | NCT06053567 |
| Nicotine patch | Other | Phase PHASE3 | Nicotine Dependence | RECRUITING | NCT06053567 |
| Counseling | Other | Phase PHASE3 | Nicotine Dependence | RECRUITING | NCT06053567 |
| Aerobic Exercise | Other | Phase PHASE3 | Nicotine Dependence | RECRUITING | NCT06053567 |
| Nicotine patch | Other | Phase PHASE3 | Nicotine Dependence | RECRUITING | NCT06053567 |
| Counseling | Other | Phase PHASE3 | Nicotine Dependence | RECRUITING | NCT06053567 |
| Aerobic Exercise | Other | Phase PHASE3 | Nicotine Dependence | RECRUITING | NCT06053567 |
| Nicotine patch | Other | Phase PHASE3 | Nicotine Dependence | RECRUITING | NCT06053567 |
| Counseling | Other | Phase PHASE3 | Nicotine Dependence | RECRUITING | NCT06053567 |
| Aerobic Exercise | Other | Phase PHASE3 | Nicotine Dependence | RECRUITING | NCT06053567 |
| Nicotine patch | Other | Phase PHASE3 | Nicotine Dependence | RECRUITING | NCT06053567 |
| Counseling | Other | Phase PHASE3 | Nicotine Dependence | RECRUITING | NCT06053567 |
| Aerobic Exercise | Other | Phase PHASE3 | Nicotine Dependence | RECRUITING | NCT06053567 |
| Nicotine patch | Other | Phase PHASE3 | Nicotine Dependence | RECRUITING | NCT06053567 |
| Counseling | Other | Phase PHASE3 | Nicotine Dependence | RECRUITING | NCT06053567 |
| Aerobic Exercise | Other | Phase PHASE3 | Nicotine Dependence | RECRUITING | NCT06053567 |
| Nicotine patch | Other | Phase PHASE3 | Nicotine Dependence | RECRUITING | NCT06053567 |
| Counseling | Other | Phase PHASE3 | Nicotine Dependence | RECRUITING | NCT06053567 |
| Aerobic Exercise | Other | Phase PHASE3 | Nicotine Dependence | RECRUITING | NCT06053567 |
| Nicotine patch | Other | Phase PHASE3 | Nicotine Dependence | RECRUITING | NCT06053567 |
| Counseling | Other | Phase PHASE3 | Nicotine Dependence | RECRUITING | NCT06053567 |
| Aerobic Exercise | Other | Phase PHASE3 | Nicotine Dependence | RECRUITING | NCT06053567 |
| Nelfinavir and Omeprazole | Other | Phase PHASE4 | Healthy Volunteers | COMPLETED | NCT00251030 |
| Nelfinavir and Omeprazole | Other | Phase PHASE4 | Healthy Volunteers | COMPLETED | NCT00251030 |
| Nelfinavir and Omeprazole | Other | Phase PHASE4 | Healthy Volunteers | COMPLETED | NCT00251030 |
| Humanized anti-CD117 Monoclonal Antibody (JSP191) | Other | Phase PHASE1 | MYELODYSPLASTIC SYNDROME; MDS | UNKNOWN | NCT04429191 |
| Clinician and Non-clinician staff training | Other | Approved | LGBT Health | COMPLETED | NCT03554785 |
| Clinician and Non-clinician staff training | Other | Approved | LGBT Health | COMPLETED | NCT03554785 |
| Tumor resection | Other | Preclinical | Glioblastoma | RECRUITING | NCT06146738 |
| Tumor biopsy | Other | Preclinical | Glioblastoma | RECRUITING | NCT06146738 |
| Palliative Care | Other | Preclinical | Glioblastoma | RECRUITING | NCT06146738 |
| Tumor resection | Other | Preclinical | Glioblastoma | RECRUITING | NCT06146738 |
| Tumor biopsy | Other | Preclinical | Glioblastoma | RECRUITING | NCT06146738 |
| Palliative Care | Other | Preclinical | Glioblastoma | RECRUITING | NCT06146738 |
| Tumor resection | Other | Preclinical | Glioblastoma | RECRUITING | NCT06146738 |
| Tumor biopsy | Other | Preclinical | Glioblastoma | RECRUITING | NCT06146738 |
| Palliative Care | Other | Preclinical | Glioblastoma | RECRUITING | NCT06146738 |
| Tumor biopsy | Other | Preclinical | Glioblastoma | RECRUITING | NCT06146725 |
| Tumor resection | Other | Preclinical | Glioblastoma | RECRUITING | NCT06146725 |
| Tumor biopsy | Other | Preclinical | Glioblastoma | RECRUITING | NCT06146725 |
| Tumor resection | Other | Preclinical | Glioblastoma | RECRUITING | NCT06146725 |
| Maximal safe resection | Other | Preclinical | Glioblastoma | RECRUITING | NCT06118723 |
| Supramaximal resection | Other | Preclinical | Glioblastoma | RECRUITING | NCT06118723 |
| Maximal safe resection | Other | Preclinical | Glioblastoma | RECRUITING | NCT06118723 |
| Supramaximal resection | Other | Preclinical | Glioblastoma | RECRUITING | NCT06118723 |
| JSP191 | Other | Phase PHASE1 | Lower-risk Myelodysplastic Syndrome | TERMINATED | NCT05903274 |
| Humanized anti-CD117 Monoclonal Antibody (JSP191) | Other | Phase PHASE1 | SCID | TERMINATED | NCT02963064 |
| Placebo Comparator | Other | Phase PHASE1 | Allergic Asthma | TERMINATED | NCT06592768 |
| Briquilimab | Other | Phase PHASE1 | Allergic Asthma | TERMINATED | NCT06592768 |
| Briquilimab | Other | Phase PHASE1 | Chronic Inducible Urticaria | TERMINATED | NCT06353971 |
| Placebo | Other | Phase PHASE1 | Chronic Spontaneous Urticaria | ACTIVE_NOT_RECRUITING | NCT06162728 |
| Briquilimab | Other | Phase PHASE1 | Chronic Spontaneous Urticaria | ACTIVE_NOT_RECRUITING | NCT06162728 |
| Briquilimab | Other | Phase PHASE2 | Urticaria Chronic | ACTIVE_NOT_RECRUITING | NCT06736262 |
| Nelfinavir and Omeprazole | DRUG | Phase PHASE4 | Healthy Volunteers | COMPLETED | NCT00251030 |
| Placebo Comparator | OTHER | Phase PHASE1 | Allergic Asthma | TERMINATED | NCT06592768 |
| Placebo | OTHER | Phase PHASE1 | Chronic Spontaneous Urticaria | ACTIVE_NOT_RECRUITING | NCT06162728 |
| Briquilimab | DRUG | Phase PHASE2 | Urticaria Chronic | ACTIVE_NOT_RECRUITING | NCT06736262 |
| JSP191 | DRUG | Phase PHASE1 | Lower-risk Myelodysplastic Syndrome | TERMINATED | NCT05903274 |
| Humanized anti-CD117 Monoclonal Antibody (JSP191) | BIOLOGICAL | Phase PHASE1 | MYELODYSPLASTIC SYNDROME; MDS | UNKNOWN | NCT04429191 |
Total products: 87